ArticleGynecologic oncology reports2026
Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Standards for practical management of drug hypersensitivity reactions to intravenous drugs and proactive early allergy involvement before referral: A WAO Statement.The World Allergy Organization journal · 2026Review
- Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023.Gynecologic oncology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare survival between gynecologic cancer patients with carboplatin hypersensitivity thereafter managed with carboplatin desensitization, cisplatin replacement, and alternative non-platinum therapy. Methods: A retrospective review of patients who experienced a hypersensitivity reaction to carboplatin and were treated at the same comprehensive cancer center between 2010 and 2024 was completed. The primary analysis compared progression-free survival between carboplatin desensitization, cisplatin substitution, and alternative non-platinum therapy patients. Secondary analysis compared survival between platinum therapy and non-platinum alternative therapy patients. Descriptive analysis was further performed to delineate the clinical phenotypes of patients with carboplatin hypersensitivity. Results: There were 47 gynecologic cancer patients with carboplatin hypersensitivity, and 38 patients with known progression-free survival. Progression-free survival was significantly longer in desensitized patients (31.1 months) vs. cisplatin patients (22.0 months, p = 0.045). There were no significant differences in progression-free survival between desensitized (31.3 months) and alternative therapy patients (36.0 months), as well as platinum (31.1 months) and non-platinum-based alternative therapy patients (36.0 months). A majority of our cohort was observed to have recurrent disease at the time of hypersensitivity (70.2 %), a carboplatin-free interval of 12 months or more (57.4 %), history of adverse reactions to other drugs (76.6 %), advanced stage disease (78.8 %), and serous histology (70.2 %). Conclusions: Desensitized patients demonstrated increased progression-free survival as compared to cisplatin patients. This progression-free survival advantage may be due to the increased toxicity profiles noted for cisplatin and comparatively better tolerability of carboplatin desensitization. Progression-free survival was similar between carboplatin-desensitized and alternative therapy patients, as well as platinum-based and alternative therapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.